Status:
COMPLETED
Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-Infected Patients in Virological Failure.
Lead Sponsor:
French National Agency for Research on AIDS and Viral Hepatitis
Conditions:
HIV Infections
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
HIV infected patients are treated with highly active antiretroviral therapy (HAART). Side effects and the great number of pills reduces adherence to the treatment, and induces therapeutic failure. In ...
Detailed Description
HIV infected patients are treated with highly active antiretroviral therapy (HAART). Side effects and the great number of pills reduces adherence to the treatment, and induces therapeutic failure. In ...
Eligibility Criteria
Inclusion
- Documented HIV infection
- CD4 cell count below 300/mm3
- Plasma HIV RNA over 30,000 copies/ml
- Previously treated with 2 protease inhibitors and 1 non nucleoside analogue (except amprenavir, lopinavir)
- Written informed consent
Exclusion
- Biological abnormalities
- Pregnancy
- Alcool abuse
- History of pancreatitis, hepatic failure
- Acute HIV related infection
- Chemotherapy
Key Trial Info
Start Date :
November 1 2000
Trial Type :
INTERVENTIONAL
End Date :
February 1 2002
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00196625
Start Date
November 1 2000
End Date
February 1 2002
Last Update
September 20 2005
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.